Targeting microRNA-122 to Treat Hepatitis C Virus Infection
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
An important host factor for hepatitis C virus (HCV) is microRNA-122 (miR-122). miR-122 is a liver-specific member of a family of small, non-coding RNA molecules known as microRNAs that play major roles in the regulation of gene expression by direct interaction with RNA targets. miR-122 binds directly to two sites in the 5′ untranslated region (UTR) of HCV RNA and positively regulates the viral life cycle. The mechanism by which this regulation occurs is still not fully understood. There has been a great deal of interest in potential therapeutics based on small RNAs, and targeting miR-122 to combat HCV is one of the furthest advanced. Chemical inhibitors of miR-122 can be introduced into mammals intravenously and result in potent and specific knockdown of the microRNA, with no detectable adverse effects on liver physiology. This strategy was recently applied to chimpanzees chronically infected with HCV and resulted in a sustained reduction in viral load in the animals. Inhibition of miR-122 therefore presents a very attractive novel approach to treating HCV, a virus for which improved therapeutics are urgently needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
Esau, C., Davis, S., Murray, S. F., Yu, X. X., Pandey, S. K., Pear, M., Watts, L., Booten, S. L., Graham, M., McKay, R., et al. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.005 · Cited by 2,082 · cited 1×
“Inhibition of miR-122 in mice was first accomplished using an ‘antagomir’ [28] and a 2′-MOE-modified oligomer with a phosphorothioate backbone [33].”
MethodLNA-mediated microRNA silencing in non-human primates
Elmén, J., Lindow, M., Schütz, S., Lawrence, M., Petri, A., Obad, S., Lindholm, M., Hedtjärn, M., Hansen, H. F., Berger, U., et al. (2008) · Nature · doi:10.1038/nature06783 · Cited by 1,589 · cited 4×
“One interesting difference was that the cholesterol reduction in chimpanzees was predominantly in low-density lipoprotein (LDL) and apolipoprotein Apo-B, in contrast to African green monkeys where high-density lipoprotein (HDL) and its apolipoprotein Apo-A1 were mainly affected [25,26].”
BackgroundMethodResultInfluentialIn situ detection of miRNAs in animal embryos using LNA-modified oligonucleotide probes
Kloosterman, W. P., Wienholds, E., de Bruijn, E., Kauppinen, S., & Plasterk, R. H. A. (2006) · Nature Methods · doi:10.1038/nmeth843 · Cited by 599
Sequence-specific inhibition of small RNA function
Hutvágner, G., Simard, M. J., Mello, C. C., & Zamore, P. D. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020098 · Cited by 584 · cited 1×
“The first application of this approach used an RNA oligomer complementary to the miRNA let-7, with 2′-O-methyl (2′-OMe) modifications at each position [21].”
MethodImproved targeting of miRNA with antisense oligonucleotides
Davis, S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl183 · Cited by 422
Cited by
Advances in oligonucleotide drug delivery
Roberts, T. C., Langer, R., & Wood, M. J. A. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0075-7 · Cited by 2,027
Parsi, S., Smith, P. Y., Goupil, C., Dorval, V., & Hébert, S. S. (2015) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2015.33 · Cited by 83
Choi, J. E., Hur, W., Kim, J.-H., Li, T. Z., Lee, E. B., Lee, S. W., Kang, W., Shin, E.-C., Wakita, T., & Yoon, S. K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091958 · Cited by 12
Metadata
- Authors
- Jopling, C. L.
- Venue
- Viruses
- Publisher
- MDPI AG
- Published
- 2010-07-05
- Volume
- 2
- Issue
- 7
- Pages
- 1382-1393
- ISSN
- 1999-4915 (ISSN-L)
- OpenAlex
- W1971273590
- Cited by
- 52
- References
- 5
- FWCI
- 1.51
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting microRNA-122 to Treat Hepatitis C Virus Infection. https://app.cochat.ai/papers/10.3390/v2071382
- The paper
- Jopling, C. L. (2010). Targeting microRNA-122 to Treat Hepatitis C Virus Infection. Viruses. https://doi.org/10.3390/v2071382
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.